Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 98Stomach Neoplasms 50Rectal Neoplasms 45Pancreatic Neoplasms 45Colonic Neoplasms 36Esophageal Neoplasms 34Neoplasms 30Neoplasm Metastasis 28Squamous Cell Carcinoma of Head and Neck 27Head and Neck Neoplasms 24Breast Neoplasms 21Adenocarcinoma Of Esophagus 20Parkinson Disease 4, Autosomal Dominant Lewy Body 12Adenocarcinoma 9Anus Neoplasms 8Esophageal Squamous Cell Carcinoma 7Carcinoma, Squamous Cell 7Carcinoma 7Cholangiocarcinoma 6Liver Neoplasms 5Gallbladder Neoplasms 5Bile Duct Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Adenocarcinoma 4Gastrointestinal Neoplasms 4Carcinoma, Hepatocellular 4Skin Neoplasms 3Sarcoma 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3

Interventions

Irinotecan 3pembrolizumab 1napabucasin 1Leucovorin 1KRN-330 1Fluorouracil 1Cyclophosphamide 1Bevacizumab 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rectal Diseases × Fluorouracil × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡